Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK-J4 + PKF118-310 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK-J4 | GSK-J4 is a specific inhibitor of KDM6, which results in increased H3K27 tri-methylation and induction of DNA damage response and cell death (PMID: 22842901, PMID: 26759175, PMID: 32525734, PMID: 32477122, PMID: 32514253). | |||
PKF118-310 | CTNNB1 Inhibitor 27 KDM4 Inhibitor 4 | PKF118-310 inhibits KDM4A activity (PMID: 27767379) and the CTNNB1/TCF interaction, which results in apoptosis and anti-tumor activity (PMID: 19662654). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|